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Abstract
Chronic Myeloid Leukemia (CML) is a stem cell cancer that arises when t(9;22) translocation occurs in a hematopoietic
stem cells. This event results in the expression of the BCR-ABL1 fusion gene, which codes for a constitutively active
tyrosine kinase that is responsible for the transformation of a HSC into a CML stem cell, which then gives rise to a
clonal myeloproliferative disease. The introduction of Tyrosine Kinase Inhibitors (TKIs) has revolutionized the
management of the disease. However, these drugs do not seem to be able to eradicate the malignancy. Indeed,
discontinuation trials (STIM; TWISER; DADI) for those patients who achieved a profound molecular response showed
50% relapsing within 12 months. We performed a comparative analysis on 15 CML patients and one B-ALL patient,
between the standard quantitative reverse-transcriptase PCR (qRT–PCR) and our genomic DNA patient-speciﬁc
quantitative PCR assay (gDNA qPCR). Here we demonstrate that gDNA qPCR is better than standard qRT–PCR in
disease monitoring after an average follow-up period of 200 days. Speciﬁcally, we statistically demonstrated that DNA
negativity is more reliable than RNA negativity in indicating when TKIs therapy can be safely stopped.
Introduction
Chronic Myeloid Leukemia (CML) is a classic example
of a stem cell cancer and arises when the t(9;22) trans-
location (the Philadelphia chromosome)1–3 occurs in a
hematopoietic stem cell (HSC). This event results in the
expression of the BCR-ABL1 fusion gene, which codes for
a constitutively active tyrosine kinase responsible for the
transformation of a HSC into a CML stem cell, and thence
to a clonal myeloproliferative disease.
The BCR-ABL1 fusion gene exists in three different
forms, associated with different types of leukemia: p190 is
mainly associated with Ph-positive (Ph+) acute lympho-
blastic leukemia (ALL), p210 with 95% of CML, and p230
with a subset of patients with chronic neutrophilic leu-
kemia (CNL). There is, however, some overlap. P210
occurs in 40% of Ph+ ALL, p190 occurs in 2–3% of CML,
and p230 in some cases of CML4.
Until a little more than a decade ago, drug therapy for
CML was limited to nonspeciﬁc agents such as busulfan,
hydroxyurea, and interferon α (INF-a)5. Allogeneic stem
cell transplantation (allo-SCT) is curative, but carries risks
of morbidity and mortality; and furthermore, allo-SCT is
an option only for patients with good performance status
and organ functions, and who have an appropriate stem
cell donor6. The introduction of a potent BCR-ABL1
tyrosine kinase inhibitor (TKI), Imatinib (IM), almost two
decades ago, followed by subsequent generations of TKI,
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has transformed the management of CML7,8. However,
these drugs are not able to eradicate the malignancy, and
patients therefore require life-long therapy.
Most cases achieve a major molecular response (MMR)
in which BCR-ABL1 levels detectable by qPCR (quanti-
tative PCR) in the blood show a 3log10 fold reduction
9.
However, due to patient-to-patient variation, 10–20% of
all patients develop even deeper molecular responses
triggering dose de-escalation and discontinuation/stop-
ping trials (STIM10, TWISTER11, DADI12, EURO-SKI) in
which 50% of patients relapse within 12 months. TKI
discontinuation studies demonstrated that stopping TKI
therapy should thus be performed only under the auspices
of a clinical trial6.
Strong evidence now shows that CML leukemic stem
cells (LSCs) persist in most patients on long-term therapy,
and may promote acquired TKI resistance, driving relapse
or disease progression. Virtually all chronic phase (CP)
patients on TKI therapy and in MMR are not cured of
CML and show signs of residual disease burden from the
presence of LSCs in the bone marrow (BM). Although
LSCs are not always detectable in cases of very deep
molecular response—most likely from technical limitations
- some patients with no detectable LSCs can subsequently
relapse after TKI discontinuation13–16. Other studies have
shown that the LSCs which persist in patient in MMR
express BCR-ABL1 at lower levels than the LSCs at the
time of diagnosis. Furthermore, murine BM cells engi-
neered to express low levels of BCR-ABL1 were far less
sensitive to IM, whereas those expressing higher levels
were prone to de novo mutations17. Tessa et al.14
demonstrated that in vitro and in vivo knockdown of BCR-
ABL resulted in LSCs persistence, and these cells resulted
independent of BCR-ABL kinase activity, therefore
underlying that targeting BCR-ABL kinase activity alone is
not sufﬁcient to eliminate them14. Thus, the eradication of
LSCs inevitably represent a bottleneck to cure.
Quantitative reverse-transcriptase PCR (qRT–PCR) is
the most sensitive technique now available to monitor
BCR-ABL1 fusion transcripts. In 2006, the National
Institute of Health Consensus Group proposed an inter-
national scale (IS) to standardize the results18. Despite
high qRT–PCR sensitivity, this technique has limits rela-
ted to the interpretation of undetectable results. The
mRNA molecule is susceptible to degradation, and
the efﬁciency of cDNA synthesis can vary19. Indeed, the
accuracy of the method critically depends on the ability of
testing laboratories to measure absolute numbers of
control gene transcripts in a comparable manner and
achieve the sensitivity required for the BCR-ABL1
detection20,21. Finally, this technique detects leukemic
transcripts, which may not be proportional to the number
of Philadelphia positive cells; and it completely misses
transcriptionally silent cells22.
Responding to these limitations, we have developed a
gDNA patient-speciﬁc qPCR assay to detect leukemic
cells irrespective of their transcriptional status, and a
formula to calculate the number of leukemic cells23. By
comparing qRT–PCR and gDNA qPCR on 15 CML
patients and one B-ALL (B-cell acute lymphoblastic leu-
kemia) patient, we statistically proved for the ﬁrst time the
superiority of the DNA marker to monitor leukemic cells
in late follow-up (after a median of 200 days of therapy).
Materials and methods
Patients
All patients gave their informed consent to participate
in this study.
We monitored 15 patients with CML diagnosed in Chronic
Phase (CP) and one with B-ALL for an average period of
72 months (patients’ characteristics are listed in Table 1).
Patients included 9 men and 7 women, with a median age
at diagnosis of 49 years (range 13–67 years). 11/16 patients
showed a b2a2 fusion transcript; 4/16 showed a b3a2 fusion
transcript and 1/16 showed a p190 transcript. The majority
of patients were treated with Imatinib (Gleevec®, STI571,
Novartis) monotherapy at a starting dose of 400mg/day,
except for patient 5, who participated in an 800mg/day
trial and patient 11, who participated in a NILG 09/2000
protocol (ClinicalTrial.gov Identiﬁer NCT00.58072) with a
600mg/day IM dose. Patient 5 continued therapy with IM
800mg/day until 64 months, when the dosage was reduced
to 400mg/day. The dose for patients 6 and 8 was increased
to 600mg/day as a consequence of suboptimal cytogenetic
ﬁndings observed at 12 and 6 months, respectively. Patients
6 and 8 continued therapy with IM 600mg/day until 73
and 44 months, respectively, after which dosage was
reduced to 400mg/day. Therapy for patient 9 was changed
to Dasatinib 100mg/day after 17 months due to skin
toxicity (grade III) and then reduced to 50mg/day because
of gastrointestinal toxicity. After 47 months, patient 9 fol-
lowed a dose escalation to Dasatinib 80mg/day, which
elicited a MMR. The therapy for patient 10 was changed in
Nilotinib 600mg/day at 12 months due to MMR loss, but
later suspended do to cardiological toxicity and substituted
with Dasatinib 100mg/day (which elicited a MMR). Patient
11 followed a dose de-escalation to IM 400mg/day until
the transplant, followed by a dose of 200mg/day. Patient 12
reached a stable deep molecular response (4.5 log10 fold
reduction of BCR-ABL transcripts) and suspended the
therapy after 78 months of therapy. Patient 14 interrupted
IM therapy due to MMR loss after 51 months of therapy,
then he switched to Dasatinib 100mg/day and followed a
dose de-escalation at 50mg/dye Dasatinib due to diabetic
nephropathy-related chronic renal failure. Patient 16 sus-
pended IM therapy after 14 months due to severe anemia,
thrombocytopenia and bowel bleeding; then he followed a
restart of IM 400mg/day. For patient 13 (pediatric at
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diagnosis) no information about the therapy dosage are
available.
Monitoring
ELN (European LeukemiaNet) recommends to assess
and monitor the response using both conventional cyto-
genetics (Chromosome Banding Analysis (CBA) of at least
20 marrow cells metaphases) and real-time qPCR21.
Cytogenetics was performed at 3, 6, and 12 months, until
a complete cytogenetic response (CCyR) was achieved.
Once a CCyR is achieved, CBA can be substituted by
FISH (ﬂuorescence in situ hybridization) of at least 200
blood cells nuclei. qRT–PCR was performed on total
white blood cells (WBC) every 3 months. The results of
qRT–PCR are expressed according to the International
Scale (IS) as BCR-ABL1%18,20,24. BCR was used as refer-
ence gene. Once a major molecular response (BCR-ABL1
≤0.1%IS) has been achieved, qRT–PCR was performed
every 3–6 months, depending on baseline risk, transcripts
level, and transcripts level ﬂuctuations.
We collected bone marrow (BM) and peripheral blood
(PB) samples from 15 newly diagnosed CML patients and
one B-ALL patient, from the ASST Papa Giovanni XXIII
(Bergamo, Italy) and from Ospedale di Circolo e Fonda-
zione Macchi (Varese, Italy). We followed these patients for
an average period of 72 months. For each patient, real-time
qPCR (RTq–PCR) and gDNA qPCR25 were used to
determine the BCR-ABL1 over BCR values on all analyzed
samples. Values below detection of the qRT–PCR assay
were converted to positive BCR-ABL1 values due to the
logarithmic transformation, since undetectable BCR-ABL1
transcripts don’t correspond to a leukemic cells absence.
All mRNA analyses were performed following the
standard operating procedures of the LabNet and
GIMEMA CML Working Party.
BCR-ABL1 DNA breakpoint fusion sequences of 8/16
patients were previously characterized through a system
originally developed for genome walking25, while the
remainder 8 fusion sequences were characterized with
Enrichment (Sure Select Target Enrichment – Agilent
Technologies) and Next Generation Sequencing methods
(HiSeq instrument, Illumina). Brieﬂy, genomic DNA was
extracted from peripheral blood or bone marrow, frag-
mented, ligated to adaptors and enriched in the region of
interest (3 regions for BCR, corresponding to major,
minor and micro breakpoint regions, and 1 for ABL).
Enriched DNA was then ampliﬁed and sequenced
through an HiSeq sequencing instrument. Sequencing
data were processed in order to identify genomic BCR-
ABL1 breakpoints coordinates in chromosome 22 and 9
Table 1 CML patients’ characteristics
Patient Sex Age at diagnosis
(years)
Date of
Diagnosis
Diagnosis Translocation Start of therapy Therapymg/die
1 M 59 21/02/2006 CML t(9;22)(q34;q11)p210 b2a2 07/03/2006 IM 400mg/die
2 + M 66 06/06/2005 CML t(9;22)(q34;q11)p210 b2a2 17/06/2005 IM 400mg/die
3 M 60 20/05/2005 CML t(9;22)(q34;q11)p210 b2a2 25/05/2005 IM 400mg/die
4 M 50 30/03/2005 CML t(9;22)(q34;q11)p210 b2a2 12/04/2005 IM 400mg/die
5 F 71 03/02/2005 CML t(9;22)(q34;q11)p210 b2a2 14/02/2005 IM 800mg/die
6 F 63 02/12/2004 CML t(9;22)(q34;q11)p210 b2a2 21/12/2004 IM 400mg/die
7 M 52 8/10/2004 CML t(9;22)(q34;q11)p210 b2a2 12/10/2004 IM 400mg/die
8 M 60 30/05/2005 CML t(9;22)(q34;q11;q24)p210 b2a2 08/06/2005 IM 400mg/die
9 F 70 13/09/2007 CML t(9;22)(q34;q11)p210 b2a2 24/09/2007 IM 400mg/die
10 F 70 02/10/2007 CML t(9;22)(q34;q11)p210 b2a2 20/10/2007 IM 400mg/die
11a M 66 03/08/2006 B-ALL t(9;22)(q34;q11)p190 02/09/2006 IM 600mg/die
12 M 74 12/07/2010 CML t(9;22)(q34;q11)p210 b3a2 16/07/2010 IM 400mg/die
13 F 20 04/08/2010 CML t(9;22)(q34;q11)p210 b3a2 Not available Not available
14b F 49 20/08/2010 CML t(9;22)(q34;q11)p210 b3a2 25/08/2010 IM 400mg/die
15 M 48 02/11/2010 CML (X;9;22)(p11;q34;q11)(ABL+ BCR+ ;
ABL+BCR-)p210 b2a2
05/11/2010 IM 400mg/die
16 F 67 16/12/2010 CML t(9;22(q34;q11)p210 b3a2 21/12/2010 IM 400mg/die
aPatients 2 and 11 died in 2010 and 2009, respectively
bBCR-ABL1 coordinates for patient 14 were taken from the derivative chromosome 9
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for each patient. These coordinates were then used to
designed a patient-speciﬁc assay, which comprises two
real-time reactions: one directed against the breakpoint
sequence (present in one copy only in leukemic cells), and
a second directed against the BCR sequence (present in
one copy in leukemic cells and in two copies in normal
cells).
Informed consent was obtained in accordance with the
Declaration of Helsinki principles and with approval of
the Ethic Committees of Insubria University, Ospedale di
Circolo e Fondazione Macchi (Varese, Italy) and ASST
Papa Giovanni XXIII (Bergamo, Italy).
Statistical analysis
Statistical correlation analysis of data was performed
with Wolfram mathematica and Fortran software.
Results
Our laboratory developed a patient-speciﬁc DNA-based
assay to detect leukemic cells independent of their tran-
scriptional status. We have previously published the
results obtained by comparing our gDNA qPCR to stan-
dard qRT–PCR on eight newly diagnosed Chronic Phase
CML patients; our technique resulted positive in more
than 30% of samples with undetectable mRNA22,26.
The results from gDNA qPCR and RT–qPCR analysis
on all 16 patients are reported in Figs. 1 and 2.
Several studies16,27–31 based on BCR-ABL1 transcript
measurements in CML patients showed a biphasic or
triphasic exponential decline of leukemic cell number.
The slopes of the resulting curves indicated the presence
of different cell populations; the ﬁrst slope represents the
turnover rate of differentiated leukemic cells, while the
second (and third) slope represents the turnover rate of
leukemic progenitors (or stem cells). To understand the
correlation between DNA and mRNA values, we ﬁrst
evaluated the distribution of DNA measurements after
9 months of therapy, when the number of leukemic cells
is <1% (low sensitivity zone) in most of the tested
patients. We hypothesized that the second slope repre-
sents the persistence of leukemic cells resistant to TKI
treatment. Considering these parameters, we obtained
132 pairs of values and calculated the mean (µ=
2.20785), variance (σ2= 1.0850), and skewness (γ=
0.16704) of these values. The skewness value suggested a
symmetric distribution, and to test this hypothesis we
performed a Kolmogorov-Smirnov test (implemented in
Wolfram Mathematica). We conﬁrmed the hypothesis
with 95% reliability.
To test for any gDNA and mRNA value correlation, we
constructed a scatter plot (Fig. 3a) which showed no
signiﬁcant correlation (r= 0.6003).
We then tried to estimate a correlation by a different
approach. First, we considered the 132 mRNA values and
tested whether these were normally distributed as DNA
values. The Kolmogorov-Smirnov test showed a non-
Gaussian distribution of these values (p > 0.05). We then
considered the “area of agreement” between DNA and
mRNA values (Fig. 3b).
The results showed that only 56% of mRNA values fell
within the DNA conﬁdence interval, but 89% of measures
outside this conﬁdence interval were undetectable
mRNA values. These results suggest that the
difference between these two measures (DNA vs. RNA)
might lie in undetectable values. Therefore, we studied the
correlation (ρ) between DNA and mRNA values over
time; the results within the ﬁrst 10 months are shown in
Fig. 2c.
We observed a decrease in correlation between 100 and
200 days of therapy, which corresponded to the decay of
cell number to below 1%. Finally, we performed a con-
ditioned correlation test (by choosing a threshold; Fig. 3d)
between two arrays deﬁned in the following way: we chose
a threshold value of DNA (or mRNA) marker, then we
considered the under-threshold measurements for the
selected marker and the measurements made on the same
sample with the other marker. For undetectable values
(when using zero as threshold), because the variance is
null, we used joint probability as an estimator of corre-
lation. Results showed a low correlation between these
arrays, but it is notable that DNA undetectable values
were always correlated with mRNA null values; contra-
riwise, mRNA undetectable values have only a 21.3%
probability to be correlated to DNA null values.
Discussion and Conclusions
In most patients under TKI therapy, there is a pro-
gressive decline in BCR-ABL1 transcripts over time.
However, CML has been suggested as impossible to cure,
due to the persistence of leukemic stem cells that cannot
be eradicated by TKI treatment. Whether all CML cells
have been eradicated in any patient is a question of sig-
niﬁcant clinical and scientiﬁc importance16.
We have previously demonstrated that our gDNA qPCR
assay proves residual disease positivity in more than 30%
of mRNA negative samples22,26.
In this study, we performed a comparative statistical
analysis of both mRNA and DNA BCR-ABL1 values in 15
CML patients (7 new and 8 previously published) and one
B-ALL patient, in order to investigate if our gDNA
technique is more reliable to identify transcriptionally
silent leukemic cells, which could be responsible for
relapse after TKIs discontinuation. As reported in the
literature32–34, our results indicate a 3-fold decrease in
BCR-ABL1 gene and transcript within the ﬁrst 2 years of
therapy. By plotting the Log10(BCR-ABL) values over
time, after 10 months (i.e. after the 3log fold decay) nearly
95% of cases showed a number of leukemic cells reduced
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more than 99%. Considering these cases (under 1%
region) we noticed a great difference in undetectable value
distribution between DNA and mRNA: 17 BCR-ABL1
DNA negative samples vs. 81 mRNA negative samples.
Indeed, there was weak agreement between DNA and
RNA values (56%), and the decrease in correlation was
consistent after the initial 3-fold decay in leukemic cell
number. Our data analysis also showed that when we
considered DNA as a threshold in correlation analysis,
there’s always a correspondence (100% joint probability)
between undetectable values of DNA with that of RNA;
contrariwise, considering RNA as a threshold value, there
Fig. 1 DNA vs. mRNA quantitative PCR results. The ﬁgure displays the kinetics of the leukemic cell burden in patients treated with Imatinib
mesylate after the diagnosis in early chronic phase. (a–h) The panels show the percentage of cancer cells (BCR-ABL1/BCR) as measured by gDNA
qPCR (⊗DNA values, solid line) and RT–qPCR (▲RNA values, dashed line) in patients 1–8
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was only a 21% joint probability (i.e., undetectable RNA
values were rarely correlated to DNA null values).
We infer that after an average period of 200 days of
therapy, BCR-ABL1 detection with gDNA qPCR is
more reliable to determine the absence of leukemic
cells and, therefore, could be more reliable for the
clinicians’ decision on whether to discontinue TKI
therapy.
Many researchers have proposed mathematical models
to describe the differentiation hierarchy of the hemato-
poietic system16,27–31. Most of these studies were con-
ducted on BCR-ABL transcript values from CML patients
Fig. 2 DNA vs. mRNA quantitative PCR results. The ﬁgure displays the kinetics of the leukemic cell burden in patients treated with Imatinib
mesylate after the diagnosis in early chronic phase. (I-P) The panels show the percentage of cancer cells (BCR-ABL1/BCR) as measured by gDNA qPCR
(⊗DNA values, solid line) and RT–qPCR (▲RNA values, dashed line) in patients 9 to 16
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and showed a biphasic or triphasic exponential decline of
leukemic cell number. The slopes of the resulting curves
indicated the presence of different cell populations: the ﬁrst
slope represents the turnover rate of differentiated leu-
kemic cells, while the second (and third) slope represent
the turnover rate of leukemic progenitors (or stem cells).
Our DNA data seem to ﬁt with these RNA-based mathe-
matical models, as we obtained a biphasic decline of leu-
kemic cells for almost all our patients; however, we were
not able to calculate the ﬁrst slope of the curve, due to the
paucity of measurements in the ﬁrst 12 months of therapy.
Moreover, the molecular response at 3 months of TKI
therapy has prognostic signiﬁcance; a BCR-ABL1 tran-
script level >10%IS at 3 months is associated with sig-
niﬁcantly inferior overall free survival (OS), progression-
free survival (PFS), failure-free survival (FFS) and cyto-
genetic and molecular responses. The National Compre-
hensive Cancer Network (NCCN) guidelines include a
change of therapy if BCR-ABL1 is >10% at 3 months,
whereas ELN suggests that a single BCR-ABL1
measurement at 3 months is insufﬁcient to deﬁne treat-
ment failure requiring a change of therapy. For patients
with >10% BCR-ABL1 at 3 months, the ELN recommends
additional testing and a change of therapy for patients
who are still >10% after 6 months of treatment.
In order to robustly identify the ﬁrst slope, a sufﬁcient
number of early time points is needed; thus, with the aim
to develop a new mathematical model to predict the effect
of TKIs on leukemic stem cells, we propose that clinicians
collect new CML samples every month for the ﬁrst
12 months of therapy. We would also include in the
resultant study CML patients who received nilotinib as
ﬁrst-line therapy, to understand whether this second-
generation TKI is more active on the leukemic stem cell
population (though Tang et al.16 concluded that Nilotinib
elicited treatment responses very similar to Imatinib).
The application of our DNA-based method to CD34+
sorted cells (stem cells) could also provide additional
information about the stem cell compartment composi-
tion in CML patients at diagnosis and during treatment.
Fig. 3 Statistical analysis between DNA and RNA measures. a The correlation between the two methods used for CML samples analysis. On x axis
are reported the DNA values, while y axis represents the mRNA values. The dashed line is the equality line (X= Y). If there was no or little differences
between DNA and RNA measures, the values should have followed the equality line. Our results are clearly not correlated. b The agreement between
DNA and RNA values. The area comprised between the two dashed lines represents the 95% conﬁdence interval of DNA values (not null) after
9 months of therapy. Dots represents the mRNA values coupled to DNA ones. Only 56% of mRNA values falls within the DNA conﬁdence interval, but
the 89% of measures outside this conﬁdence interval are undetectable mRNA values. c The correlation between DNA and RNA values over time. On
the x axis is the time (expressed in months), while on the y axis is the correlation (ρ) value. We observe a decrease in correlation between 100 and
200 days of therapy, which correspond to the decay of cells’ number under 1%. d The conditionate correlation vs. a threshold value. On x axis is the
threshold value, while y axis is the correlation (ρ) value. The solid line represents the DNA threshold, while the dashed line represents the mRNA
threshold. When we choose DNA as a threshold and we consider undetectable values, DNA and mRNA showed 100% correspondence; but we
obtained a very low correlation in all the other follow-ups
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